Weather

86°F4:17 PM

Health

1 read

Novo Nordisk Cuts Prices of Ozempic and Wegovy by 50% Starting 2027

KVIA•Tuesday, February 24, 2026 at 4:04 PM•CNN Newsource

Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

AI Summary

Novo Nordisk has announced a significant reduction in the list prices of its popular diabetes and weight loss medications, Ozempic, Wegovy, and Rybelsus, by up to 50% starting in 2027. The current list price for Wegovy is $1,349, while Ozempic and Rybelsus are priced at $1,028. This price cut aims to improve accessibility for patients, particularly those with high deductibles or co-insurance plans. The move comes as Novo Nordisk competes with Eli Lilly, which has gained market share in the obesity medication sector. Despite the list price reductions, self-pay prices will remain unaffected. The company recently reported disappointing trial results for its next-generation obesity drug, contributing to a decline in its stock price.

Key Details: • List prices for Wegovy and Ozempic reduced by up to 50% effective 2027. • Current Wegovy price: $1,349; Ozempic and Rybelsus: $1,028. • Insurance holders may pay as low as $25 a month for these medications. • New self-pay patients can access discounted rates for the first two months.

health medications ozempic wegovy price-reduction

People & Organizations

Novo NordiskEli Lilly

Related Articles

Study Suggests HEPA Air Purifiers Could Enhance Cognitive Function in Adults Over 40

Recent research indicates that air pollution can impair mental function within hours, particularly affecting adults over 40. The study highlights the potential benefits of using HEPA air purifiers to mitigate these effects and improve cognitive abilities. This finding is significant as it underscores the importance of clean air for maintaining brain health, especially for older adults who may be more vulnerable to pollution-related cognitive decline. Residents are encouraged to consider air purification solutions to enhance their home environment and protect their mental well-being.

New Study Reveals Rising Use of Psilocybin Among Americans

A recent study indicates that approximately 8 million Americans have consumed psilocybin, commonly known as 'magic mushrooms,' in the past year. The findings highlight that usage is particularly prevalent among young adults, men, and white individuals. This trend suggests a growing acceptance and potential therapeutic use of psilocybin, prompting clinicians to consider incorporating questions about its use into routine patient assessments. Understanding this shift in substance use is crucial for healthcare providers as they navigate treatment options.

Recent Study Reveals 8 Million Americans Tried Psilocybin in Last Year

A recent study indicates that approximately 8 million Americans have experimented with psilocybin, commonly known as 'magic mushrooms,' over the past year. The findings highlight a demographic trend where young adults, particularly men and white individuals, are more inclined to use this substance compared to other groups. This surge in usage suggests that healthcare providers should incorporate inquiries about psilocybin use into standard patient assessments, emphasizing the need for awareness and understanding of its effects and implications in clinical settings.

El Paso to Participate in National Prescription Drug Take Back Day This Saturday

This Saturday, April 25, the U.S. Drug Enforcement Administration (DEA) will conduct its 30th National Prescription Drug Take Back Day, providing a crucial opportunity for residents to safely dispose of unused or expired medications. The event will take place from 10 a.m. to 2 p.m. at nearly 4,200 locations across the country, including several in El Paso. This initiative is vital for preventing drug misuse and protecting the environment. Residents are encouraged to participate and help reduce the risk of prescription drug abuse in the community.